Exploitation of Fibrinolytic Enzymes in Combating Blood Clotting Disorders – Recent Advances and Strategies: A Comprehensive Review

Sahoo, Sheela Kumari; Sahoo, Sabuj

doi:10.1007/978-981-15-2195-9_25

Cited by 2 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), fungi (Asperigillus sp., Penicillium sp., Trichothecium sp., S. cerevisiae), algae, and actinomycetes in the process of urokinase-production (Agrawal & Patil, 2020;Nawaz et al, 2020). The evident attainment of high yields of urokinase from microbial sources validate their acceptance over pre-existing sources of UPA (Sahoo & Sahoo, 2020). In addition, the availability of factors including microbial source, physical parameters, and the cultural conditions make the process sensitive to multi-faceted optimization strategies.…”

Section: Urokinasementioning

confidence: 99%

“…Streptokinases are neither proteases nor true plasminogen activators like urokinases (Avgerinos, 2017). They bind to one of the circulating plasminogen molecules to form a streptokinase-plasminogen complex (Figure 1), the resulting conformational changes (Figure 2) favor the conversion of surrounding plasminogen to active plasmin (Aghaeepoor et al, 2019;Sahoo & Sahoo, 2020). Urokinase, unlike streptokinase, is a true plasminogen activator and having been isolated from urine, it is often called UPA: urinary-type plasminogen activator.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Production and market comparison of urokinase and streptokinase as effective and cheap fibrinolytic agents for treatment of cardiovascular diseases

Nawaz¹,

Haq

Amin

et al. 2022

Acta Sci Technol

View full text Add to dashboard Cite

Failure of hemostasis and the formation of blood clots in the arteries are the main reasons that provoke the onset of cardiovascular diseases (CVDs) such as myocardial infarction and ischemic stroke. Cardiovascular diseases have become the primary cause of deaths and disabilities across the globe. Therefore, this problem needs to be addressed with urgency. The disintegration of blood clots requires fibrinolytic agents, which are involved in thrombolysis. Streptokinase and urokinase are fibrinolytic enzymes; the former is primarily produced from microbial sources and the latter is isolated from urine, respectively. Streptokinase and urokinase have been in use for a long time to treat cardiovascular diseases. This review explains in detail the comparison of employing streptokinase and urokinase for the said purpose in a cost-effective manner. The recombinant production of both the agents has been discussed in detail. Furthermore, the efficacy of both the agents has been compared based upon their side effects and retention time in the body. A thorough study has been made to compare the influence of using both the agents on the health of cardiovascular patients in the last decade.

show abstract

Section: Urokinasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%